Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors

Chemotherapy-induced thrombocytopenia (CIT) is a common complication in cancer patients, especially after multiple cycles of chemotherapy, which leads to the delayed treatment or reduced dosage. The treatment of CIT is limited for refractory and severe cases. Herein we reported a single-center study...

Full description

Bibliographic Details
Main Authors: Yanting Gao, Qi Liu, Yingying Shen, Yuzhu Li, Keding Shao, Baodong Ye, Yiping Shen, Yuhong Zhou, Dijiong Wu
Format: Article
Language:English
Published: Taylor & Francis Group 2022-10-01
Series:Platelets
Subjects:
avatrombopag
chemotherapy-induced thrombocytopenia
refractory
severe
thrombopoietin receptor agonist
Online Access:http://dx.doi.org/10.1080/09537104.2022.2026910

Internet

http://dx.doi.org/10.1080/09537104.2022.2026910

Similar Items